Virtu Financial’s Windtree Therapeutics WINT Stock Holding History

Virtu Financial’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-43	Closed	-$28K	–	2167
2023 Q4	$28K	Buy	+43	New	+$37.9K	﹤0.01%	1267
2023 Q3	–	Sell	-47	Closed	-$54K	–	1966
2023 Q2	$54K	Buy	+47	New	+$95.4K	﹤0.01%	1134
2023 Q1	–	Sell	-1	Closed	-$4K	–	2156
2022 Q4	$4K	Sell	1 -1	-50%	-$8.89K	﹤0.01%	1460
2022 Q3	$30K	Buy	+2	New	+$35.7K	﹤0.01%	1320
2022 Q2	–	Hold	0	–	–	–	1454

Other funds holding WINT

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Virtu Financial's WINT Position: Q1 2024 in Review

Virtu Financial sold out of Windtree Therapeutics (WINT) in Q1 2024, closing a stake of 43 shares — an estimated $28K sold.

Virtu Financial first reported a position in WINT in Q3 2022 and held it in 4 quarters. The position peaked at $54K in Q2 2023. 4 funds tracked by Wall St. Rank hold WINT as of Q1 2024.

Virtu Financial reported no remaining Windtree Therapeutics position as of Q1 2024 after selling out during the quarter.
Virtu Financial sold 43 Windtree Therapeutics shares in Q1 2024, an estimated $28K.
Virtu Financial first reported a position in Windtree Therapeutics in Q3 2022 and held it in 4 quarters.
Virtu Financial's Windtree Therapeutics position peaked at $54K in Q2 2023.
4 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.